KR20140069332A - 항원 제거를 촉진하는 에프씨알엔 결합 도메인을 갖는 치료학적 항원 결합 분자 - Google Patents
항원 제거를 촉진하는 에프씨알엔 결합 도메인을 갖는 치료학적 항원 결합 분자 Download PDFInfo
- Publication number
- KR20140069332A KR20140069332A KR1020147011698A KR20147011698A KR20140069332A KR 20140069332 A KR20140069332 A KR 20140069332A KR 1020147011698 A KR1020147011698 A KR 1020147011698A KR 20147011698 A KR20147011698 A KR 20147011698A KR 20140069332 A KR20140069332 A KR 20140069332A
- Authority
- KR
- South Korea
- Prior art keywords
- antigen
- binding
- fcrn
- binding domain
- binding molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000009739 binding Methods 0.000 title claims abstract description 902
- 239000000427 antigen Substances 0.000 title claims abstract description 592
- 102000036639 antigens Human genes 0.000 title claims abstract description 592
- 108091007433 antigens Proteins 0.000 title claims abstract description 591
- 230000001225 therapeutic effect Effects 0.000 title description 21
- 230000027455 binding Effects 0.000 claims abstract description 1139
- 230000007935 neutral effect Effects 0.000 claims abstract description 170
- 230000001965 increasing effect Effects 0.000 claims abstract description 147
- 238000000034 method Methods 0.000 claims abstract description 92
- 108010068617 neonatal Fc receptor Proteins 0.000 claims abstract description 90
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims abstract description 83
- 230000002378 acidificating effect Effects 0.000 claims abstract description 63
- 239000003814 drug Substances 0.000 claims abstract description 31
- 229940079593 drug Drugs 0.000 claims abstract description 29
- 230000001404 mediated effect Effects 0.000 claims abstract description 8
- 230000036470 plasma concentration Effects 0.000 claims abstract description 7
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims abstract 79
- 235000001014 amino acid Nutrition 0.000 claims description 240
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 182
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 179
- 235000002374 tyrosine Nutrition 0.000 claims description 179
- 150000001413 amino acids Chemical group 0.000 claims description 173
- 229940024606 amino acid Drugs 0.000 claims description 159
- 238000006467 substitution reaction Methods 0.000 claims description 159
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 74
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 70
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 69
- 239000004474 valine Substances 0.000 claims description 69
- 235000014393 valine Nutrition 0.000 claims description 69
- 235000013922 glutamic acid Nutrition 0.000 claims description 63
- 239000004220 glutamic acid Substances 0.000 claims description 63
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 63
- 235000004554 glutamine Nutrition 0.000 claims description 63
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 54
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 54
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 52
- 235000004279 alanine Nutrition 0.000 claims description 52
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 49
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 48
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 42
- 230000001419 dependent effect Effects 0.000 claims description 39
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 36
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 35
- 239000004473 Threonine Substances 0.000 claims description 35
- 235000008521 threonine Nutrition 0.000 claims description 35
- 239000004475 Arginine Substances 0.000 claims description 33
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 33
- 235000009697 arginine Nutrition 0.000 claims description 33
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 33
- 235000014304 histidine Nutrition 0.000 claims description 33
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 32
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 28
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 27
- 235000003704 aspartic acid Nutrition 0.000 claims description 27
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 27
- 235000013930 proline Nutrition 0.000 claims description 27
- 108090000623 proteins and genes Proteins 0.000 claims description 27
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 24
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 24
- 229960000310 isoleucine Drugs 0.000 claims description 24
- 235000014705 isoleucine Nutrition 0.000 claims description 24
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 23
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 22
- 235000004400 serine Nutrition 0.000 claims description 22
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 21
- 239000004472 Lysine Substances 0.000 claims description 21
- 235000018977 lysine Nutrition 0.000 claims description 21
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 20
- 239000002253 acid Substances 0.000 claims description 20
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 18
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 17
- 239000011575 calcium Substances 0.000 claims description 17
- 229910052791 calcium Inorganic materials 0.000 claims description 17
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 16
- 235000005772 leucine Nutrition 0.000 claims description 16
- 230000002829 reductive effect Effects 0.000 claims description 14
- 230000008859 change Effects 0.000 claims description 11
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 claims description 11
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims description 11
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Chemical group OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 10
- 235000009582 asparagine Nutrition 0.000 claims description 10
- 229960001230 asparagine Drugs 0.000 claims description 10
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 9
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 8
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 8
- 239000013628 high molecular weight specie Substances 0.000 claims description 8
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims description 7
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 7
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims description 6
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 5
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims description 5
- 229940003871 calcium ion Drugs 0.000 claims description 5
- 229910001424 calcium ion Inorganic materials 0.000 claims description 5
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims description 4
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 3
- 230000003247 decreasing effect Effects 0.000 claims description 2
- 230000001737 promoting effect Effects 0.000 claims description 2
- 230000005847 immunogenicity Effects 0.000 abstract description 22
- 238000004519 manufacturing process Methods 0.000 abstract description 10
- 230000015556 catabolic process Effects 0.000 abstract description 5
- 238000006731 degradation reaction Methods 0.000 abstract description 5
- 230000004044 response Effects 0.000 description 120
- 125000003275 alpha amino acid group Chemical group 0.000 description 94
- 241000282414 Homo sapiens Species 0.000 description 82
- 206010057190 Respiratory tract infections Diseases 0.000 description 78
- 210000002381 plasma Anatomy 0.000 description 45
- 102000005962 receptors Human genes 0.000 description 37
- 108020003175 receptors Proteins 0.000 description 37
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 27
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 24
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 19
- 230000000694 effects Effects 0.000 description 19
- 235000018102 proteins Nutrition 0.000 description 18
- 102000004169 proteins and genes Human genes 0.000 description 18
- 230000009467 reduction Effects 0.000 description 18
- 239000007924 injection Substances 0.000 description 15
- 238000002347 injection Methods 0.000 description 15
- 210000002966 serum Anatomy 0.000 description 15
- 239000012636 effector Substances 0.000 description 14
- 230000035772 mutation Effects 0.000 description 14
- 210000001163 endosome Anatomy 0.000 description 13
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 12
- 108010073807 IgG Receptors Proteins 0.000 description 12
- 102000009490 IgG Receptors Human genes 0.000 description 12
- 108010069112 Complement System Proteins Proteins 0.000 description 11
- 102000000989 Complement System Proteins Human genes 0.000 description 11
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 11
- 241000699660 Mus musculus Species 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 238000011830 transgenic mouse model Methods 0.000 description 11
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 10
- -1 R) Chemical compound 0.000 description 10
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 9
- 208000025747 Rheumatic disease Diseases 0.000 description 7
- 230000003042 antagnostic effect Effects 0.000 description 7
- 238000010494 dissociation reaction Methods 0.000 description 7
- 230000005593 dissociations Effects 0.000 description 7
- 238000003780 insertion Methods 0.000 description 7
- 230000037431 insertion Effects 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 238000011068 loading method Methods 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 230000000552 rheumatic effect Effects 0.000 description 7
- 108020001507 fusion proteins Proteins 0.000 description 6
- 102000037865 fusion proteins Human genes 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 239000012491 analyte Substances 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 229930182817 methionine Natural products 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 4
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000013595 glycosylation Effects 0.000 description 4
- 238000006206 glycosylation reaction Methods 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 108010031480 Artificial Receptors Proteins 0.000 description 2
- PDECQIHABNQRHN-GUBZILKMSA-N Asp-Glu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(O)=O PDECQIHABNQRHN-GUBZILKMSA-N 0.000 description 2
- 241000282836 Camelus dromedarius Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 108010008165 Etanercept Proteins 0.000 description 2
- 102000009109 Fc receptors Human genes 0.000 description 2
- 108010087819 Fc receptors Proteins 0.000 description 2
- KASDBWKLWJKTLJ-GUBZILKMSA-N Glu-Glu-Met Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(O)=O KASDBWKLWJKTLJ-GUBZILKMSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 239000007987 MES buffer Substances 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000016943 Muramidase Human genes 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000002917 arthritic effect Effects 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 150000002410 histidine derivatives Chemical class 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000004064 recycling Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 102200007444 rs869025269 Human genes 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- XJOTXKZIRSHZQV-RXHOOSIZSA-N (3S)-3-amino-4-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S,3S)-1-[[(1R,6R,12R,17R,20S,23S,26R,31R,34R,39R,42S,45S,48S,51S,59S)-51-(4-aminobutyl)-31-[[(2S)-6-amino-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1-oxohexan-2-yl]carbamoyl]-20-benzyl-23-[(2S)-butan-2-yl]-45-(3-carbamimidamidopropyl)-48-(hydroxymethyl)-42-(1H-imidazol-4-ylmethyl)-59-(2-methylsulfanylethyl)-7,10,19,22,25,33,40,43,46,49,52,54,57,60,63,64-hexadecaoxo-3,4,14,15,28,29,36,37-octathia-8,11,18,21,24,32,41,44,47,50,53,55,58,61,62,65-hexadecazatetracyclo[32.19.8.26,17.212,39]pentahexacontan-26-yl]amino]-3-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-oxobutanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)[C@@H](C)O)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@@H]4CSSC[C@H](NC(=O)[C@H](Cc5ccccc5)NC(=O)[C@@H](NC1=O)[C@@H](C)CC)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1cnc[nH]1)NC3=O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N2)C(=O)NCC(=O)N4)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XJOTXKZIRSHZQV-RXHOOSIZSA-N 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 101100436100 Caenorhabditis elegans asp-6 gene Proteins 0.000 description 1
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 1
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108010021468 Fc gamma receptor IIA Proteins 0.000 description 1
- 108010021472 Fc gamma receptor IIB Proteins 0.000 description 1
- 108091006020 Fc-tagged proteins Proteins 0.000 description 1
- 101150050927 Fcgrt gene Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- 206010071602 Genetic polymorphism Diseases 0.000 description 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
- 102100026119 High affinity immunoglobulin gamma Fc receptor IB Human genes 0.000 description 1
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
- 101000913077 Homo sapiens High affinity immunoglobulin gamma Fc receptor IB Proteins 0.000 description 1
- 101000840257 Homo sapiens Immunoglobulin kappa constant Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- 102100029205 Low affinity immunoglobulin gamma Fc region receptor II-b Human genes 0.000 description 1
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000012867 alanine scanning Methods 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000012512 bulk drug substance Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000003271 compound fluorescence assay Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 102000006815 folate receptor Human genes 0.000 description 1
- 108020005243 folate receptor Proteins 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 102000018511 hepcidin Human genes 0.000 description 1
- 108060003558 hepcidin Proteins 0.000 description 1
- 229940066919 hepcidin Drugs 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 241001515942 marmosets Species 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000009149 molecular binding Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- NRNCYVBFPDDJNE-UHFFFAOYSA-N pemoline Chemical compound O1C(N)=NC(=O)C1C1=CC=CC=C1 NRNCYVBFPDDJNE-UHFFFAOYSA-N 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000010118 platelet activation Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011218736 | 2011-09-30 | ||
| JPJP-P-2011-218736 | 2011-09-30 | ||
| JPPCT/JP2012/058603 | 2012-03-30 | ||
| PCT/JP2012/058603 WO2012133782A1 (ja) | 2011-03-30 | 2012-03-30 | 抗原結合分子の血漿中滞留性と免疫原性を改変する方法 |
| JP2012123781 | 2012-05-30 | ||
| JPJP-P-2012-123782 | 2012-05-30 | ||
| JPJP-P-2012-123773 | 2012-05-30 | ||
| JP2012123773 | 2012-05-30 | ||
| JPJP-P-2012-123781 | 2012-05-30 | ||
| JP2012123782 | 2012-05-30 | ||
| JP2012139211 | 2012-06-20 | ||
| JPJP-P-2012-139211 | 2012-06-20 | ||
| JP2012177311 | 2012-08-09 | ||
| JPJP-P-2012-177311 | 2012-08-09 | ||
| PCT/JP2012/006218 WO2013046704A2 (en) | 2011-09-30 | 2012-09-28 | THERAPEUTIC ANTIGEN-BINDING MOLECULE WITH A FcRn-BINDING DOMAIN THAT PROMOTES ANTIGEN CLEARANCE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20140069332A true KR20140069332A (ko) | 2014-06-09 |
Family
ID=47996560
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020147011698A Withdrawn KR20140069332A (ko) | 2011-09-30 | 2012-09-28 | 항원 제거를 촉진하는 에프씨알엔 결합 도메인을 갖는 치료학적 항원 결합 분자 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US10253100B2 (OSRAM) |
| EP (3) | EP2760890B1 (OSRAM) |
| JP (5) | JP6204350B2 (OSRAM) |
| KR (1) | KR20140069332A (OSRAM) |
| CN (2) | CN108948197A (OSRAM) |
| AU (2) | AU2012313670B2 (OSRAM) |
| BR (1) | BR112014007290A2 (OSRAM) |
| CA (1) | CA2850035A1 (OSRAM) |
| HK (1) | HK1257946A1 (OSRAM) |
| MX (1) | MX2014003891A (OSRAM) |
| RU (2) | RU2014117500A (OSRAM) |
| SG (2) | SG10201808187TA (OSRAM) |
| TW (3) | TW201817745A (OSRAM) |
| WO (1) | WO2013046704A2 (OSRAM) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180125036A (ko) * | 2015-09-18 | 2018-11-21 | 추가이 세이야쿠 가부시키가이샤 | Il-8에 결합하는 항체 및 그의 사용 |
| KR20200038562A (ko) * | 2016-08-05 | 2020-04-13 | 추가이 세이야쿠 가부시키가이샤 | Il-8 관련 질환의 치료용 또는 예방용 조성물 |
| US11454633B2 (en) | 2014-12-19 | 2022-09-27 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies, polypeptides containing variant Fc regions, and methods of use |
| US11891434B2 (en) | 2010-11-30 | 2024-02-06 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
| US12116414B2 (en) | 2007-09-26 | 2024-10-15 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in CDR |
| US12252532B2 (en) | 2015-12-25 | 2025-03-18 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
| US12473375B2 (en) | 2006-03-31 | 2025-11-18 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
Families Citing this family (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CL2008002886A1 (es) | 2007-09-26 | 2009-12-04 | Chugai Pharmaceutical Co Ltd | Region constante de un anticuerpo humano; anticuerpo anti-receptor de interleucina-6 (il-6) y composicion farmaceutica que la comprende. |
| NZ717429A (en) | 2008-04-11 | 2018-07-27 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
| CN112812184A (zh) | 2011-02-25 | 2021-05-18 | 中外制药株式会社 | FcγRIIb特异性Fc抗体 |
| TWI687441B (zh) | 2011-06-30 | 2020-03-11 | 中外製藥股份有限公司 | 異源二聚化多胜肽 |
| US20150050269A1 (en) | 2011-09-30 | 2015-02-19 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities |
| TW201817745A (zh) * | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子 |
| TW201945034A (zh) | 2011-09-30 | 2019-12-01 | 日商中外製藥股份有限公司 | 包含依離子濃度之條件對抗原之結合活性會改變之抗原結合分域、及於pH中性之條件下對FcRn有結合活性之FcRn結合分域、且誘導對標的抗原的免疫反應之抗原結合分子 |
| EP2787081A4 (en) * | 2011-11-30 | 2015-10-07 | Chugai Pharmaceutical Co Ltd | PHARMACEUTICAL CARRIER IN CELLS FOR THE FORMATION OF AN IMMUNOMOPLEX |
| SG11201404751UA (en) | 2012-02-09 | 2014-09-26 | Chugai Pharmaceutical Co Ltd | Modified fc region of antibody |
| CN107759686A (zh) | 2012-05-30 | 2018-03-06 | 中外制药株式会社 | 靶组织特异性抗原结合分子 |
| ES2856272T3 (es) * | 2012-05-30 | 2021-09-27 | Chugai Pharmaceutical Co Ltd | Molécula de unión a antígenos para eliminar antígenos agregados |
| JP6774164B2 (ja) | 2012-08-24 | 2020-10-21 | 中外製薬株式会社 | マウスＦｃγＲＩＩ特異的Ｆｃ抗体 |
| EP3721900A1 (en) | 2012-08-24 | 2020-10-14 | Chugai Seiyaku Kabushiki Kaisha | Fcgammariib-specific fc region variant |
| EP2970453B1 (en) | 2013-03-13 | 2019-12-04 | Prothena Biosciences Limited | Tau immunotherapy |
| KR102318483B1 (ko) | 2013-04-02 | 2021-10-27 | 추가이 세이야쿠 가부시키가이샤 | Ｆｃ영역 개변체 |
| CA2923145C (en) * | 2013-09-05 | 2025-09-16 | Amgen Inc. | MOLECULES CONTAINING FCS AND EXHIBITING PREDICTABLE, UNIFORM AND REPRODUCIBLE GLYCOFORM PROFILES |
| MX382731B (es) | 2013-09-27 | 2025-03-13 | Chugai Pharmaceutical Co Ltd | Metodo para producir heteromultimeros de polipeptidos. |
| KR20240134226A (ko) | 2013-12-04 | 2024-09-06 | 추가이 세이야쿠 가부시키가이샤 | 화합물의 농도에 따라 항원 결합능이 변화되는 항원 결합 분자 및 그의 라이브러리 |
| NZ711451A (en) | 2014-03-07 | 2016-05-27 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| US10780182B2 (en) | 2014-04-25 | 2020-09-22 | The Trustees Of The University Of Pennsylvania | Methods and compositions for treating metastatic breast cancer and other cancers in the brain |
| JP6974943B2 (ja) | 2014-05-13 | 2021-12-01 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | ２種の抗体構築物を発現するａａｖを含む組成物およびこの使用 |
| MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
| TWI617580B (zh) | 2014-12-19 | 2018-03-11 | 中外製藥股份有限公司 | 抗ｃ５抗體及使用方法 |
| US10464999B2 (en) | 2015-01-28 | 2019-11-05 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| US9879080B2 (en) | 2015-01-28 | 2018-01-30 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| US10633433B2 (en) | 2015-01-28 | 2020-04-28 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| MA41459A (fr) | 2015-02-03 | 2017-12-12 | Als Therapy Development Inst | Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l |
| KR102605798B1 (ko) | 2015-02-05 | 2023-11-23 | 추가이 세이야쿠 가부시키가이샤 | 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용 |
| EP4269440A3 (en) | 2015-02-27 | 2024-02-28 | Chugai Seiyaku Kabushiki Kaisha | Composition for treating il-6-related diseases |
| FR3038517B1 (fr) | 2015-07-06 | 2020-02-28 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Utilisation de fragments fc modifies en immunotherapie |
| FR3039832A1 (fr) * | 2015-08-04 | 2017-02-10 | Univ Francois Rabelais De Tours | Igg1 et leur utilisation therapeutique |
| JP6953020B2 (ja) * | 2015-09-08 | 2021-10-27 | セリピオン， インコーポレイテッド | ＡｐｏＡ−１融合ポリペプチドならびに関連する組成物および方法 |
| JP2019501115A (ja) | 2015-10-28 | 2019-01-17 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 遺伝子治療のためのアデノ随伴ウイルスベクターのくも膜下腔内投与 |
| TWI605057B (zh) | 2015-12-18 | 2017-11-11 | 中外製藥股份有限公司 | 抗肌抑素抗體、含變異ｆｃ區之多肽及使用方法 |
| KR102895909B1 (ko) * | 2016-03-14 | 2025-12-05 | 유니버시티에트 이 오슬로 | 변경된 FcRn 결합을 갖는 조작된 면역글로불린 |
| US11332544B2 (en) * | 2016-04-21 | 2022-05-17 | Merck Sharp & Dohme Corp. | Glycan-based antibody-drug conjugates |
| PT3452507T (pt) | 2016-05-02 | 2022-12-20 | Prothena Biosciences Ltd | Imunoterapia anti-tau |
| SG11201808434WA (en) | 2016-05-02 | 2018-10-30 | Prothena Biosciences Ltd | Antibodies recognizing tau |
| CN109475630A (zh) | 2016-05-27 | 2019-03-15 | 瑞颂医药公司 | 治疗难治性全身型重症肌无力的方法 |
| TWI760396B (zh) | 2016-06-17 | 2022-04-11 | 日商中外製藥股份有限公司 | 抗肌抑素抗體及使用方法 |
| US20190185578A1 (en) | 2016-07-29 | 2019-06-20 | Chugai Seiyaku Kabushiki Kaisha | Bispecific antibody exhibiting increased alternative fviii-cofactor-function activity |
| IL315729A (en) | 2016-08-02 | 2024-11-01 | Visterra Inc | Fc region containing polypeptides and uses thereof |
| SG10201607778XA (en) | 2016-09-16 | 2018-04-27 | Chugai Pharmaceutical Co Ltd | Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use |
| KR20230073346A (ko) | 2016-11-28 | 2023-05-25 | 추가이 세이야쿠 가부시키가이샤 | 리간드 결합 활성을 조정 가능한 리간드 결합 분자 |
| TWI797097B (zh) * | 2016-11-28 | 2023-04-01 | 日商中外製藥股份有限公司 | 包含抗原結合域與運送部分的多胜肽 |
| JP7191833B2 (ja) | 2017-01-30 | 2022-12-19 | 中外製薬株式会社 | 抗スクレロスチン抗体およびその使用 |
| EP3620531A4 (en) | 2017-05-02 | 2021-03-17 | National Center of Neurology and Psychiatry | METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS |
| CN110881274B (zh) | 2017-05-02 | 2024-11-15 | 普罗塞纳生物科学有限公司 | 识别tau的抗体 |
| JP2020519291A (ja) * | 2017-05-12 | 2020-07-02 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | 組み換えフォリスタチン−ｆｃ融合タンパク質およびデュシェンヌ型筋ジストロフィーの治療における使用 |
| EP3630843A2 (en) * | 2017-05-24 | 2020-04-08 | ALS Therapy Development Institute | Therapeutic anti-cd40 ligand antibodies |
| KR102713355B1 (ko) | 2017-05-25 | 2024-10-02 | 브리스톨-마이어스 스큅 컴퍼니 | 길항작용 cd40 모노클로날 항체 및 그의 용도 |
| PT3658184T (pt) | 2017-07-27 | 2023-11-29 | Alexion Pharma Inc | Formulações de anticorpo anti-c5 de elevada concentração |
| CN111032688A (zh) * | 2017-08-11 | 2020-04-17 | 研究发展基金会 | 用于延长的血清半衰期的工程化抗体fc变体 |
| WO2019071205A1 (en) | 2017-10-06 | 2019-04-11 | Prothena Biosciences Limited | ANTI-TRANSTHYRETIN ANTIBODY |
| CN111757730A (zh) | 2017-10-06 | 2020-10-09 | 普罗塞纳生物科学有限公司 | 检测甲状腺素运载蛋白的方法 |
| BR112020008182A2 (pt) | 2017-10-26 | 2020-10-27 | Alexion Pharmaceuticals, Inc. | dosagem e administração de anticorpos anti-c5 para tratamento de hemoglobinúria paroxística noturna (hpn) e síndrome hemolítica urêmica atípica (shua) |
| CN111556895B (zh) | 2017-11-14 | 2024-09-13 | 中外制药株式会社 | 抗-c1s抗体及使用方法 |
| EP3719035A4 (en) | 2017-11-28 | 2021-09-01 | Chugai Seiyaku Kabushiki Kaisha | POLYPEPTIDE INCLUDING AN ANTIGEN BINDING DOMAIN AND A TRANSPORT SECTION |
| CN111630062A (zh) | 2017-11-28 | 2020-09-04 | 中外制药株式会社 | 具有可调节的配体结合活性的配体结合分子 |
| BR112020010483A2 (pt) | 2017-11-29 | 2020-10-20 | Prothena Biosciences Limited | formulação liofilizada de um anticorpo monoclonal contra transtirretina |
| US11629198B2 (en) | 2017-12-05 | 2023-04-18 | The Trustees Of The University Of Pennsylvania | Fusion proteins and antibodies targeting human red blood cell antigens |
| KR20200132938A (ko) | 2018-03-15 | 2020-11-25 | 추가이 세이야쿠 가부시키가이샤 | 지카 바이러스에 대해 교차-반응성을 갖는 항-뎅기 바이러스 항체 및 사용 방법 |
| WO2019230867A1 (en) | 2018-05-30 | 2019-12-05 | Chugai Seiyaku Kabushiki Kaisha | Polypeptide comprising aggrecan binding domain and carrying moiety |
| JP7520725B2 (ja) | 2018-05-31 | 2024-07-23 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 小児患者における発作性夜間ヘモグロビン尿症（ｐｎｈ）の治療のための抗ｃ５抗体の用量および投与 |
| WO2019235426A1 (ja) | 2018-06-04 | 2019-12-12 | 中外製薬株式会社 | 細胞質内での半減期が変化した抗原結合分子 |
| US12460012B2 (en) | 2018-06-04 | 2025-11-04 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-C5 antibodies for treatment of atypical hemolytic uremic syndrome (aHUS) in pediatric patients |
| EP3814373A1 (en) | 2018-06-28 | 2021-05-05 | Alexion Pharmaceuticals, Inc. | Methods of producing anti-c5 antibodies |
| SG10202106830VA (en) | 2018-08-10 | 2021-08-30 | Chugai Pharmaceutical Co Ltd | Anti-cd137 antigen-binding molecule and utilization thereof |
| SG11202103313RA (en) | 2018-09-06 | 2021-04-29 | Cidara Therapeutics Inc | Compositions and methods for the treatment of viral infections |
| US12240893B2 (en) | 2018-10-30 | 2025-03-04 | Alexion Pharmaceuticals, Inc. | Subcutaneous dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH) |
| PE20211867A1 (es) * | 2018-11-01 | 2021-09-21 | Shandong New Time Pharmaceutical Co Ltd | Anticuerpos biespecificos y su uso |
| AR117091A1 (es) | 2018-11-19 | 2021-07-07 | Bristol Myers Squibb Co | Anticuerpos monoclonales antagonistas contra cd40 y sus usos |
| CN113227131B (zh) * | 2018-12-20 | 2025-03-04 | 豪夫迈·罗氏有限公司 | 经修饰的抗体Fc及其使用方法 |
| CA3131531A1 (en) | 2019-03-03 | 2020-09-10 | Prothena Biosciences Limited | Antibodies recognizing tau |
| WO2020189748A1 (ja) | 2019-03-19 | 2020-09-24 | 中外製薬株式会社 | Ｍｔａ依存的に抗原に対する結合活性が変化する抗原結合ドメインを含む抗原結合分子及び当該抗原結合ドメイン取得用ライブラリ |
| AU2020273072A1 (en) | 2019-04-10 | 2021-12-09 | Chugai Seiyaku Kabushiki Kaisha | Method for purifying Fc region-modified antibody |
| NZ782091A (en) * | 2019-05-09 | 2025-08-29 | Merus Nv | Variant domains for multimerizing proteins and separation thereof |
| US12473353B2 (en) | 2019-05-15 | 2025-11-18 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule, a pharmaceutical composition, and a method |
| US20220323619A1 (en) * | 2019-07-02 | 2022-10-13 | Telix International Pty Ltd | Antibodies for binding psma with reduced affinity for the neonatal fc receptor |
| US20210024620A1 (en) * | 2019-07-25 | 2021-01-28 | Genzyme Corporation | Methods of Treating Antibody-Mediated Disorders with FcRn Antagonists |
| CA3152009A1 (en) * | 2019-08-22 | 2021-02-25 | Cidara Therapeutics, Inc. | Variant fc domains and uses thereof |
| TWI861205B (zh) | 2019-09-06 | 2024-11-11 | 美商席達拉醫療有限公司 | 用於治療病毒感染之組合物及方法 |
| CN114867532A (zh) | 2019-12-18 | 2022-08-05 | 豪夫迈·罗氏有限公司 | 双特异性抗ccl2抗体 |
| CA3162444C (en) * | 2019-12-27 | 2024-04-30 | Hitoshi KATADA | Anti-ctla-4 antibody and use thereof |
| US20230062096A1 (en) * | 2020-01-11 | 2023-03-02 | Yale University | Compositions and methods for treating, ameliorating, and/or preventing diseases or disorders caused by or associated with dnase1 and/or dnase1l3 deficiency |
| JP7634545B2 (ja) * | 2020-01-29 | 2025-02-21 | コリア ユニバーシティ リサーチ アンド ビジネス ファウンデーション | ｐＨ感応性ＦＣ変異体 |
| TWI895351B (zh) | 2020-02-12 | 2025-09-01 | 日商中外製藥股份有限公司 | 用於癌症之治療的抗cd137抗原結合分子 |
| BR112022026780A2 (pt) * | 2020-06-29 | 2023-01-17 | Hanall Biopharma Co Ltd | Formulação para anticorpo anti-fcrn |
| US20230416371A1 (en) | 2020-08-28 | 2023-12-28 | Chugai Seiyaku Kabushiki Kaisha | Heterodimer fc polypeptide |
| CN113063949B (zh) * | 2021-03-23 | 2024-11-15 | 中国医学科学院输血研究所 | 一种血浆中特异性IgM抗体的定量测定方法 |
| AR125344A1 (es) | 2021-04-15 | 2023-07-05 | Chugai Pharmaceutical Co Ltd | Anticuerpo anti-c1s |
| US20250076283A1 (en) | 2021-05-19 | 2025-03-06 | Chugai Seiyaku Kabushiki Kaisha | Method for predicting in vivo pharmacokinetics of molecule |
| CN117500829A (zh) | 2021-06-18 | 2024-02-02 | 豪夫迈·罗氏有限公司 | 双特异性抗ccl2抗体 |
| US12448451B2 (en) | 2021-06-25 | 2025-10-21 | Chugai Seiyaku Kabushiki Kaisha | Anti-CTLA-4 antibody and use thereof |
| CN119838007A (zh) | 2021-06-25 | 2025-04-18 | 中外制药株式会社 | 抗ctla-4抗体的用途 |
| WO2022270611A1 (ja) | 2021-06-25 | 2022-12-29 | 中外製薬株式会社 | 抗ｃｔｌａ－４抗体 |
| WO2024092031A1 (en) | 2022-10-25 | 2024-05-02 | Seismic Therapeutic, Inc. | VARIANT IgG FC POLYPEPTIDES AND USES THEREOF |
Family Cites Families (235)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4769320A (en) | 1982-07-27 | 1988-09-06 | New England Medical Center Hospitals, Inc. | Immunoassay means and methods useful in human native prothrombin and human abnormal prothorombin determinations |
| JPS58201994A (ja) | 1982-05-21 | 1983-11-25 | Hideaki Hagiwara | 抗原特異的ヒト免疫グロブリンの生産方法 |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| JPH06104071B2 (ja) | 1986-08-24 | 1994-12-21 | 財団法人化学及血清療法研究所 | 第▲ｉｘ▼因子コンホメ−シヨン特異性モノクロ−ナル抗体 |
| US4801687A (en) | 1986-10-27 | 1989-01-31 | Bioprobe International, Inc. | Monoclonal antibody purification process using protein A |
| US4851341A (en) | 1986-12-19 | 1989-07-25 | Immunex Corporation | Immunoaffinity purification system |
| US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| US4803247A (en) | 1987-10-27 | 1989-02-07 | Allied-Signal Inc. | Polyamide compositions having nitrile rubber and copolymer of ethylene and alpha-olefin therein |
| JPH01144991A (ja) | 1987-12-02 | 1989-06-07 | Kagaku Oyobi Ketsusei Riyouhou Kenkyusho | 血液凝固第８因子の精製方法 |
| US5322678A (en) | 1988-02-17 | 1994-06-21 | Neorx Corporation | Alteration of pharmacokinetics of proteins by charge modification |
| JPH0636741B2 (ja) | 1989-11-08 | 1994-05-18 | 帝人株式会社 | ヒト・プロテインｃの分離方法 |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ES2139598T3 (es) | 1990-07-10 | 2000-02-16 | Medical Res Council | Procedimientos para la produccion de miembros de parejas de union especifica. |
| CA2089661C (en) | 1990-08-29 | 2007-04-03 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| DE122009000019I1 (de) | 1991-04-25 | 2009-07-16 | Chugai Seiyaku K K 5 1 | Rekombinierte humane antikörper gegen den humanen interleukin-6 rezeptor |
| AU665025B2 (en) | 1991-09-23 | 1995-12-14 | Cambridge Antibody Technology Limited | Production of chimeric antibodies - a combinatorial approach |
| ES2227512T3 (es) | 1991-12-02 | 2005-04-01 | Medical Research Council | Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago. |
| DE69333823T2 (de) | 1992-03-24 | 2006-05-04 | Cambridge Antibody Technology Ltd., Melbourn | Verfahren zur herstellung von gliedern von spezifischen bindungspaaren |
| SG48760A1 (en) | 1992-07-24 | 2003-03-18 | Abgenix Inc | Generation of xenogenetic antibodies |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| JPH08511423A (ja) | 1993-06-10 | 1996-12-03 | ジェネティック セラピー，インコーポレイテッド | 血友病治療のためのアデノウイルスベクター |
| GB9313509D0 (en) | 1993-06-30 | 1993-08-11 | Medical Res Council | Chemisynthetic libraries |
| GB9314271D0 (en) | 1993-07-09 | 1993-08-18 | Inst Of Cancer The Research | Cell growth factor receptors |
| FR2707189B1 (fr) | 1993-07-09 | 1995-10-13 | Gradient Ass | Procédé de traitement de résidus de combustion et installation de mise en Óoeuvre dudit procédé. |
| IL107742A0 (en) | 1993-11-24 | 1994-02-27 | Yeda Res & Dev | Chemically-modified binding proteins |
| JPH09506508A (ja) | 1993-12-03 | 1997-06-30 | メディカル リサーチ カウンシル | 組換え結合タンパク質およびペプチド |
| WO1995015393A1 (en) | 1993-12-03 | 1995-06-08 | Asahi Kasei Kogyo Kabushiki Kaisha | Novel expression screening vector |
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| AU701342B2 (en) | 1994-07-13 | 1999-01-28 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human interleukin-8 |
| US6309636B1 (en) | 1995-09-14 | 2001-10-30 | Cancer Research Institute Of Contra Costa | Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides |
| ATE552012T1 (de) | 1994-10-07 | 2012-04-15 | Chugai Pharmaceutical Co Ltd | Hemmung des abnormalen wachstums von synovialzellen durch il-6-antagonisten als wirkstoff |
| EP0791359A4 (en) | 1994-10-21 | 2002-09-11 | Chugai Pharmaceutical Co Ltd | MEDICINE AGAINST IL-6 PRODUCTION IN DISEASES |
| US6485943B2 (en) | 1995-01-17 | 2002-11-26 | The University Of Chicago | Method for altering antibody light chain interactions |
| ATE390933T1 (de) | 1995-04-27 | 2008-04-15 | Amgen Fremont Inc | Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8 |
| AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| AU728657B2 (en) | 1996-03-18 | 2001-01-18 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| ZA976326B (en) | 1996-07-19 | 1998-02-03 | Amgen Inc | Analogs of cationic proteins. |
| SK40599A3 (en) | 1996-09-26 | 2000-06-12 | Chugai Pharmaceutical Co Ltd | Antibody against human parathormone related peptides |
| US5990286A (en) | 1996-12-18 | 1999-11-23 | Techniclone, Inc. | Antibodies with reduced net positive charge |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| US20070059302A1 (en) | 1997-04-07 | 2007-03-15 | Genentech, Inc. | Anti-vegf antibodies |
| FR2761994B1 (fr) | 1997-04-11 | 1999-06-18 | Centre Nat Rech Scient | Preparation de recepteurs membranaires a partir de baculovirus extracellulaires |
| US5897781A (en) | 1997-06-06 | 1999-04-27 | Waters Investments Limited | Active pump phasing to enhance chromatographic reproducibility |
| WO1999018212A1 (fr) | 1997-10-03 | 1999-04-15 | Chugai Seiyaku Kabushiki Kaisha | Anticorps humain naturel |
| AU752730B2 (en) | 1998-04-03 | 2002-09-26 | Chugai Seiyaku Kabushiki Kaisha | Humanized antibody against human tissue factor (TF) and process for constructing humanized antibody |
| PT2180007E (pt) | 1998-04-20 | 2013-11-25 | Roche Glycart Ag | Engenharia de glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| WO2000009560A2 (en) | 1998-08-17 | 2000-02-24 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
| US6475718B2 (en) | 1998-09-08 | 2002-11-05 | Schering Aktiengesellschaft | Methods and compositions for modulating the interaction between the APJ receptor and the HIV virus |
| JP2002531466A (ja) | 1998-12-01 | 2002-09-24 | プロテイン デザイン ラブス， インコーポレイテッド | γ−インターフェロンに対するヒト化抗体 |
| US7183387B1 (en) * | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
| KR101155191B1 (ko) | 1999-01-15 | 2012-06-13 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6972125B2 (en) | 1999-02-12 | 2005-12-06 | Genetics Institute, Llc | Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith |
| ES2568899T3 (es) | 1999-04-09 | 2016-05-05 | Kyowa Hakko Kirin Co., Ltd. | Procedimiento para controlar la actividad de una molécula inmunofuncional |
| SK782002A3 (en) | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
| SE9903895D0 (sv) | 1999-10-28 | 1999-10-28 | Active Biotech Ab | Novel compounds |
| FR2807767B1 (fr) | 2000-04-12 | 2005-01-14 | Lab Francais Du Fractionnement | Anticorps monoclonaux anti-d |
| AU6627201A (en) | 2000-05-03 | 2001-11-12 | Mbt Munich Biotechnology Gmbh | Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites |
| DK1294769T3 (da) | 2000-06-16 | 2011-04-26 | Human Genome Sciences Inc | Antistoffer der immunspecifikt binder til BLyS |
| US7417130B2 (en) | 2000-09-08 | 2008-08-26 | University Of Zurich | Collection of repeat proteins comprising repeat modules |
| EP1331266B1 (en) | 2000-10-06 | 2017-01-04 | Kyowa Hakko Kirin Co., Ltd. | Cells producing antibody compositions |
| AU1325102A (en) | 2000-10-16 | 2002-04-29 | Phylos Inc | Protein scaffolds for antibody mimics and other binding proteins |
| DK1355919T3 (da) | 2000-12-12 | 2011-03-14 | Medimmune Llc | Molekyler med længere halveringstider, sammensætninger og anvendelser deraf |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| CA2442801A1 (en) | 2001-04-02 | 2002-10-10 | Idec Pharmaceutical Corporation | Recombinant antibodies coexpressed with gntiii |
| EE200300509A (et) | 2001-04-13 | 2004-08-16 | Biogen, Inc. | Antikehad VLA-1 vastu |
| US7667004B2 (en) | 2001-04-17 | 2010-02-23 | Abmaxis, Inc. | Humanized antibodies against vascular endothelial growth factor |
| US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
| CN101240022B (zh) | 2001-06-22 | 2012-07-18 | 中外制药株式会社 | 含有抗磷脂酰肌醇蛋白聚糖3抗体的细胞生长抑制剂 |
| DE60237282D1 (de) | 2001-06-28 | 2010-09-23 | Domantis Ltd | Doppelspezifischer ligand und dessen verwendung |
| US20040161741A1 (en) | 2001-06-30 | 2004-08-19 | Elazar Rabani | Novel compositions and processes for analyte detection, quantification and amplification |
| US20030049203A1 (en) | 2001-08-31 | 2003-03-13 | Elmaleh David R. | Targeted nucleic acid constructs and uses related thereto |
| DK1562968T3 (da) | 2001-11-14 | 2013-10-28 | Janssen Biotech Inc | Anti-il-6-antistoffer, sammensætninger, fremgangsmåder og anvendelser |
| AU2002362197A1 (en) | 2001-12-28 | 2003-07-24 | Chugai Seiyaku Kabushiki Kaisha | Method of stabilizing protein |
| BR0307548A (pt) | 2002-02-11 | 2006-01-17 | Genentech Inc | Método de produção de uma variante de anticorpo, variante de anticorpo, composição, ácido nucléico isolado, vetor, célula hospedeira, processo para a produção de uma variante de anticorpo e método de determinação do coeficiente de associação de antìgeno de um anticorpo |
| AR038568A1 (es) | 2002-02-20 | 2005-01-19 | Hoffmann La Roche | Anticuerpos anti-a beta y su uso |
| US20080199471A1 (en) | 2002-03-01 | 2008-08-21 | Bernett Matthew J | Optimized cd40 antibodies and methods of using the same |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
| US7662925B2 (en) | 2002-03-01 | 2010-02-16 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| AU2003217912A1 (en) | 2002-03-01 | 2003-09-16 | Xencor | Antibody optimization |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| DE60326839D1 (de) | 2002-06-12 | 2009-05-07 | Genencor Int | Verfahren zur verbesserung einer bindungseigenschaft eines moleküls |
| US20060141456A1 (en) | 2002-06-12 | 2006-06-29 | Cynthia Edwards | Methods and compositions for milieu-dependent binding of a targeted agent to a target |
| US8193318B2 (en) | 2002-08-14 | 2012-06-05 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
| WO2004016740A2 (en) | 2002-08-15 | 2004-02-26 | Epitomics, Inc. | Humanized rabbit antibodies |
| KR100980065B1 (ko) | 2002-09-27 | 2010-09-03 | 젠코어 인코포레이티드 | 최적화된 Ｆｃ 변이체 및 그의 제조 방법 |
| RU2390527C2 (ru) | 2002-09-27 | 2010-05-27 | Ксенкор, Инк. | АНТИТЕЛО, СОДЕРЖАЩЕЕ Fc-ВАРИАНТНУЮ ЧАСТЬ (ВАРИАНТЫ), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ АНТИТЕЛО, И СПОСОБ ЛЕЧЕНИЯ МЛЕКОПИТАЮЩЕГО |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| AU2003286467B2 (en) | 2002-10-15 | 2009-10-01 | Abbvie Biotherapeutics Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| CA2511910A1 (en) | 2002-12-27 | 2004-07-15 | Domantis Limited | Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand |
| US7960512B2 (en) | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| EP1608684A2 (en) | 2003-02-07 | 2005-12-28 | Protein Design Labs, Inc. | Amphiregulin antibodies and their use to treat cancer and psoriasis |
| EP1601697B1 (en) | 2003-02-28 | 2007-05-30 | Lonza Biologics plc | Antibody purification by Protein A and ion exchange chromatography |
| US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
| US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
| GB2401040A (en) | 2003-04-28 | 2004-11-03 | Chugai Pharmaceutical Co Ltd | Method for treating interleukin-6 related diseases |
| KR100973564B1 (ko) | 2003-05-02 | 2010-08-03 | 젠코어 인코포레이티드 | 최적화된 Ｆｃ 변이체 및 그의 제조 방법 |
| CA2528434A1 (en) | 2003-06-05 | 2005-01-06 | Genentech, Inc. | Combination therapy for b cell disorders |
| NZ544486A (en) | 2003-06-13 | 2009-04-30 | Biogen Idec Inc | Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof |
| JP2007504245A (ja) | 2003-09-05 | 2007-03-01 | ジェネンテック・インコーポレーテッド | 変更したエフェクター機能を有する抗体 |
| JP2005101105A (ja) | 2003-09-22 | 2005-04-14 | Canon Inc | 位置決め装置、露光装置、デバイス製造方法 |
| US8101720B2 (en) | 2004-10-21 | 2012-01-24 | Xencor, Inc. | Immunoglobulin insertions, deletions and substitutions |
| AU2003271174A1 (en) | 2003-10-10 | 2005-04-27 | Chugai Seiyaku Kabushiki Kaisha | Double specific antibodies substituting for functional protein |
| WO2005037867A1 (en) | 2003-10-15 | 2005-04-28 | Pdl Biopharma, Inc. | ALTERATION OF Fc-FUSION PROTEIN SERUM HALF-LIVES BY MUTAGENESIS OF POSITIONS 250, 314 AND/OR 428 OF THE HEAVY CHAIN CONSTANT REGION OF IG |
| CA2543360A1 (en) | 2003-10-24 | 2005-05-06 | Joost A. Kolkman | Ldl receptor class a and egf domain monomers and multimers |
| WO2005049649A1 (en) | 2003-11-05 | 2005-06-02 | Ares Trading S.A. | Process for the purification of il-18 binding protein |
| WO2005047327A2 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
| NZ547157A (en) | 2003-12-10 | 2009-07-31 | Medarex Inc | Interferon Alpha Antibodies and their uses |
| EP1697520A2 (en) | 2003-12-22 | 2006-09-06 | Xencor, Inc. | Fc polypeptides with novel fc ligand binding sites |
| PE20051053A1 (es) | 2004-01-09 | 2005-12-12 | Pfizer | ANTICUERPOS CONTRA MAdCAM |
| PT1706424E (pt) * | 2004-01-12 | 2009-10-01 | Applied Molecular Evolution | Variantes da região fc |
| US7276585B2 (en) | 2004-03-24 | 2007-10-02 | Xencor, Inc. | Immunoglobulin variants outside the Fc region |
| US20050260711A1 (en) | 2004-03-30 | 2005-11-24 | Deepshikha Datta | Modulating pH-sensitive binding using non-natural amino acids |
| WO2005123780A2 (en) | 2004-04-09 | 2005-12-29 | Protein Design Labs, Inc. | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
| WO2005112564A2 (en) | 2004-04-15 | 2005-12-01 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Germline and sequence variants of humanized antibodies and methods of making and using them |
| AU2005247301B2 (en) | 2004-04-16 | 2011-08-18 | Macrogenics, Inc. | FCγRIIB-specific antibodies and methods of use thereof |
| AR049390A1 (es) | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
| NZ582684A (en) | 2004-06-18 | 2011-05-27 | Ambrx Inc | Use of an antibody or binding fragment thereof comprising a non naturally encoded amino acid coupled to a linker |
| EP1773391A4 (en) | 2004-06-25 | 2009-01-21 | Medimmune Inc | INCREASING THE PRODUCTION OF RECOMBINANT ANTIBODIES IN MAMMALIAN CELLS BY MUTAGENESIS ON THE SITE |
| DE102004032634A1 (de) | 2004-07-06 | 2006-02-16 | Sms Demag Ag | Verfahren und Einrichtung zum Messen und Regeln der Planheit und/oder der Bandspannungen eines Edelstahlbandes oder einer Edelstahlfolie beim Kaltwalzen in einem Vielwalzengerüst, insbesondere in einem 20-Walzen-Sendizimir-Walzwerk |
| EP2940043A1 (en) | 2004-07-15 | 2015-11-04 | Xencor, Inc. | Optimized fc variants |
| PL1776384T3 (pl) | 2004-08-04 | 2013-10-31 | Mentrik Biotech Llc | WARIANTY REGIONÓW Fc |
| JP4820757B2 (ja) | 2004-08-11 | 2011-11-24 | 国立大学法人京都大学 | 抗体及びその利用 |
| EP1778726A4 (en) | 2004-08-16 | 2009-03-18 | Medimmune Inc | INTEGRIN ANTAGONISTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-ASSAYED CYTOTOXICITY ACTIVITY |
| ZA200701715B (en) | 2004-08-19 | 2008-07-30 | Genentech Inc | Polypeptide variants with altered effector function |
| WO2006030200A1 (en) | 2004-09-14 | 2006-03-23 | National Institute For Biological Standards And Control | Vaccine |
| US7563443B2 (en) | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
| US20060115485A1 (en) | 2004-10-29 | 2006-06-01 | Medimmune, Inc. | Methods of preventing and treating RSV infections and related conditions |
| US7462697B2 (en) | 2004-11-08 | 2008-12-09 | Epitomics, Inc. | Methods for antibody engineering |
| US7632497B2 (en) | 2004-11-10 | 2009-12-15 | Macrogenics, Inc. | Engineering Fc Antibody regions to confer effector function |
| EP2314618A3 (en) * | 2004-11-12 | 2011-10-19 | Xencor Inc. | Fc variants with altered binding to FcRn |
| US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| RU2412200C2 (ru) | 2004-11-12 | 2011-02-20 | Ксенкор, Инк. | Fc-ВАРИАНТЫ С ИЗМЕНЕННЫМ СВЯЗЫВАНИЕМ С FcRn |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US20090061485A1 (en) | 2004-12-22 | 2009-03-05 | Chugai Seiyaku Kabushiki Kaisha | Method of Producing an Antibody Using a Cell in Which the Function of Fucose Transporter Is Inhibited |
| ES2343426T3 (es) | 2004-12-23 | 2010-07-30 | Novo Nordisk A/S | Ligandos de afinidad de union a anticuerpos. |
| US20060263357A1 (en) | 2005-05-05 | 2006-11-23 | Tedder Thomas F | Anti-CD19 antibody therapy for autoimmune disease |
| DK3050963T3 (da) | 2005-03-31 | 2019-12-09 | Chugai Pharmaceutical Co Ltd | Fremgangsmåde til fremstilling af polypeptid ved regulering af arrangement |
| AU2006230413B8 (en) | 2005-03-31 | 2011-01-20 | Xencor, Inc | Fc variants with optimized properties |
| DK2824183T3 (da) | 2005-04-08 | 2020-09-28 | Chugai Pharmaceutical Co Ltd | Fremgangsmåde til fremstilling af bispecifikke antistoffer |
| US8008443B2 (en) | 2005-04-26 | 2011-08-30 | Medimmune, Llc | Modulation of antibody effector function by hinge domain engineering |
| US8163881B2 (en) | 2005-05-31 | 2012-04-24 | The Board Of Regents Of The University Of Texas System | Immunoglobulin molecules with improved characteristics |
| EP2573114B1 (en) | 2005-08-10 | 2016-03-30 | MacroGenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| PL2407486T3 (pl) | 2005-08-19 | 2018-05-30 | Wyeth Llc | Przeciwciała antagonistyczne względem GDF-8 i zastosowania w leczeniu ALS i innych zaburzeń związanych z GDF-8 |
| DK1931709T3 (en) | 2005-10-03 | 2017-03-13 | Xencor Inc | FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES |
| US8679490B2 (en) | 2005-11-07 | 2014-03-25 | Genentech, Inc. | Binding polypeptides with diversified and consensus VH/VL hypervariable sequences |
| WO2007060411A1 (en) | 2005-11-24 | 2007-05-31 | Ucb Pharma S.A. | Anti-tnf alpha antibodies which selectively inhibit tnf alpha signalling through the p55r |
| WO2007063539A1 (en) | 2005-11-30 | 2007-06-07 | Can-Fite Biopharma Ltd. | Therapeutic uses of a3 adenosine receptor antibodies |
| JP5193881B2 (ja) | 2005-12-29 | 2013-05-08 | セントカー・インコーポレーテツド | ヒト抗ｉｌ−２３抗体、組成物、方法および用途 |
| AU2007212147A1 (en) | 2006-02-03 | 2007-08-16 | Medimmune, Llc | Protein formulations |
| DK2009101T3 (en) | 2006-03-31 | 2018-01-15 | Chugai Pharmaceutical Co Ltd | Antibody modification method for purification of a bispecific antibody |
| EP2006381B1 (en) | 2006-03-31 | 2016-02-03 | Chugai Seiyaku Kabushiki Kaisha | Method for controlling blood pharmacokinetics of antibodies |
| TWI395754B (zh) | 2006-04-24 | 2013-05-11 | Amgen Inc | 人類化之ｃ-ｋｉｔ抗體 |
| US7786270B2 (en) | 2006-05-26 | 2010-08-31 | Macrogenics, Inc. | Humanized FcγRIIB-specific antibodies and methods of use thereof |
| AU2007255753B2 (en) | 2006-06-08 | 2013-01-17 | Chugai Seiyaku Kabushiki Kaisha | Preventive or remedy for inflammatory disease |
| EP2032159B1 (en) | 2006-06-26 | 2015-01-07 | MacroGenics, Inc. | Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof |
| ES2402591T3 (es) | 2006-08-14 | 2013-05-07 | Xencor Inc. | Anticuerpos optimizados que seleccionan como diana CD19 |
| WO2008060785A2 (en) | 2006-10-06 | 2008-05-22 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Prevention of tissue ischemia, related methods and compositions |
| US20100034194A1 (en) | 2006-10-11 | 2010-02-11 | Siemens Communications Inc. | Eliminating unreachable subscribers in voice-over-ip networks |
| WO2008140603A2 (en) | 2006-12-08 | 2008-11-20 | Macrogenics, Inc. | METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING |
| PL2099826T3 (pl) | 2007-01-05 | 2014-04-30 | Univ Zuerich | Przeciwciało przeciwko beta-amyloidowi i jego zastosowania |
| CA2669412A1 (en) | 2007-01-23 | 2008-07-31 | Xencor, Inc. | Optimized cd40 antibodies and methods of using the same |
| WO2008092117A2 (en) | 2007-01-25 | 2008-07-31 | Xencor, Inc. | Immunoglobulins with modifications in the fcr binding region |
| EP2087111A2 (en) | 2007-03-19 | 2009-08-12 | Medimmune Limited | Polypeptide variants |
| US8337854B2 (en) | 2007-04-04 | 2012-12-25 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Monoclonal antibodies against dengue and other viruses with deletion in Fc region |
| WO2008143954A2 (en) | 2007-05-14 | 2008-11-27 | Biogen Idec Ma Inc. | Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto |
| ES2659517T3 (es) | 2007-05-30 | 2018-03-16 | Xencor, Inc. | Métodos y composiciones para inhibir células que expresan CD32B |
| CA2691974C (en) | 2007-06-29 | 2016-08-30 | Quest Diagnostics Investments Incorporated | Analysis of amino acids in body fluid by liquid chromatography-mass spectrometry |
| US8940872B2 (en) | 2007-07-06 | 2015-01-27 | Tokyo Metropolitan Institute Of Medical Science | Antibody binding specifically to TDP-43 aggregate |
| RU2505603C2 (ru) | 2007-09-26 | 2014-01-27 | Чугаи Сейяку Кабусики Кайся | Антитело против рецептора il-6 |
| CA2700701C (en) | 2007-09-26 | 2020-12-29 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in cdr |
| CL2008002886A1 (es) | 2007-09-26 | 2009-12-04 | Chugai Pharmaceutical Co Ltd | Region constante de un anticuerpo humano; anticuerpo anti-receptor de interleucina-6 (il-6) y composicion farmaceutica que la comprende. |
| RU2010116756A (ru) | 2007-09-28 | 2011-11-10 | Чугаи Сейяку Кабусики Кайся (Jp) | Антитело против глипикана-3 с улучшенными кинетическими показателями в плазме |
| US20100249381A1 (en) | 2007-10-22 | 2010-09-30 | David Delvaille | Method for Purifying FC-Fusion Proteins |
| WO2009062051A2 (en) | 2007-11-08 | 2009-05-14 | Pikamab, Inc. | Methods and compositions for antibody therapy |
| WO2009085200A2 (en) | 2007-12-21 | 2009-07-09 | Amgen Inc. | Anti-amyloid antibodies and uses thereof |
| KR101616758B1 (ko) | 2007-12-26 | 2016-04-29 | 젠코어 인코포레이티드 | ＦｃＲｎ에 대한 변경된 결합성을 갖는 Ｆｃ 변이체 |
| JP5373823B2 (ja) | 2008-01-29 | 2013-12-18 | アブリンクス エン．ヴェー． | タンパク質及びポリペプチドを安定化する方法 |
| NZ717429A (en) | 2008-04-11 | 2018-07-27 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| CA2722600C (en) | 2008-05-01 | 2014-01-21 | Amgen Inc. | Anti-hepcidin antibodies and methods of use |
| KR20170116193A (ko) | 2008-06-20 | 2017-10-18 | 노파르티스 아게 | 응집이 감소된 면역글로불린 |
| JP5028372B2 (ja) | 2008-09-26 | 2012-09-19 | 京セラドキュメントソリューションズ株式会社 | 画像処理装置、画像処理方法及び画像処理プログラム |
| TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
| CN110317272A (zh) | 2008-10-14 | 2019-10-11 | 霍夫曼-拉罗奇有限公司 | 免疫球蛋白变体及其用途 |
| JP5807300B2 (ja) | 2008-11-18 | 2015-11-10 | 株式会社シノテスト | 試料中のｃ反応性蛋白質の測定方法及び測定試薬 |
| CA2749339A1 (en) | 2009-01-12 | 2010-07-15 | Cytomx Therapeutics, Llc | Modified antibody compositions, methods of making and using thereof |
| JP2012515556A (ja) * | 2009-01-23 | 2012-07-12 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 低下したエフェクタ機能を有する安定化Ｆｃポリペプチドおよび使用方法 |
| US20100292443A1 (en) | 2009-02-26 | 2010-11-18 | Sabbadini Roger A | Humanized platelet activating factor antibody design using anti-lipid antibody templates |
| EP2826789A1 (en) | 2009-03-19 | 2015-01-21 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
| EP2233500A1 (en) * | 2009-03-20 | 2010-09-29 | LFB Biotechnologies | Optimized Fc variants |
| JP2010250827A (ja) | 2009-04-16 | 2010-11-04 | Accenture Global Services Gmbh | タッチポイントをカスタマイズするシステム |
| US8568726B2 (en) * | 2009-10-06 | 2013-10-29 | Medimmune Limited | RSV specific binding molecule |
| JP5734988B2 (ja) | 2009-10-06 | 2015-06-17 | メディミューン リミテド | Ｒｓｖ特異的結合分子 |
| CA2776385C (en) * | 2009-10-07 | 2019-04-09 | Macrogenics, Inc. | Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use |
| CN102971342B (zh) | 2010-01-28 | 2016-08-03 | Ab生物科学公司 | 亲和力降低的新抗体和制备所述抗体的方法 |
| LT2536745T (lt) | 2010-02-19 | 2016-09-26 | Xencor, Inc. | Nauji ctla4-ig imunoadhezinai |
| JP2011184418A (ja) | 2010-03-11 | 2011-09-22 | Tokyo Institute Of Technology | 親和性可変抗体 |
| WO2011111007A2 (en) | 2010-03-11 | 2011-09-15 | Rinat Neuroscience Corporation | ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING |
| TWI667346B (zh) * | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的FcRn親和力之抗體 |
| MX349622B (es) | 2010-09-08 | 2017-08-07 | Halozyme Inc | Metodos para evaluar e identificar o evolucionar proteinas terapeuticas condicionalmente activas. |
| CN108715614A (zh) | 2010-11-30 | 2018-10-30 | 中外制药株式会社 | 与多分子的抗原重复结合的抗原结合分子 |
| CN112812184A (zh) | 2011-02-25 | 2021-05-18 | 中外制药株式会社 | FcγRIIb特异性Fc抗体 |
| WO2012132067A1 (ja) | 2011-03-30 | 2012-10-04 | 中外製薬株式会社 | 抗原結合分子の血漿中滞留性と免疫原性を改変する方法 |
| AU2012229048B2 (en) | 2011-03-16 | 2016-01-21 | Amgen Inc | Fc variants |
| DK2698431T3 (da) | 2011-03-30 | 2020-11-30 | Chugai Pharmaceutical Co Ltd | Opretholdelse af antigen-bindende molekyler i blodplasma og fremgangsmåde til modifikation af immunogenicitet |
| WO2012162277A1 (en) | 2011-05-25 | 2012-11-29 | Merck Sharp & Dohme Corp. | METHOD FOR PREPARING Fc-CONTAINING POLYPEPTIDES HAVING IMPROVED PROPERTIES |
| UA117901C2 (uk) | 2011-07-06 | 2018-10-25 | Ґенмаб Б.В. | Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування |
| US20150050269A1 (en) | 2011-09-30 | 2015-02-19 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities |
| TW201945034A (zh) | 2011-09-30 | 2019-12-01 | 日商中外製藥股份有限公司 | 包含依離子濃度之條件對抗原之結合活性會改變之抗原結合分域、及於pH中性之條件下對FcRn有結合活性之FcRn結合分域、且誘導對標的抗原的免疫反應之抗原結合分子 |
| TW201817745A (zh) * | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子 |
| SG11201401101XA (en) | 2011-09-30 | 2014-08-28 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule for promoting loss of antigens |
| SG11201401102VA (en) * | 2011-09-30 | 2014-09-26 | Chugai Pharmaceutical Co Ltd | Ion concentration-dependent binding molecule library |
| US20150299313A1 (en) | 2011-10-05 | 2015-10-22 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule for promoting clearance from plasma of antigen comprising suger chain receptor-binding domain |
| EP2787081A4 (en) | 2011-11-30 | 2015-10-07 | Chugai Pharmaceutical Co Ltd | PHARMACEUTICAL CARRIER IN CELLS FOR THE FORMATION OF AN IMMUNOMOPLEX |
| SG11201404751UA (en) | 2012-02-09 | 2014-09-26 | Chugai Pharmaceutical Co Ltd | Modified fc region of antibody |
| TWI682939B (zh) | 2012-02-24 | 2020-01-21 | 日商中外製藥股份有限公司 | 經ＦｃγＲＩＩＢ促進抗原消失之抗原結合分子 |
| CN107759686A (zh) | 2012-05-30 | 2018-03-06 | 中外制药株式会社 | 靶组织特异性抗原结合分子 |
| ES2856272T3 (es) | 2012-05-30 | 2021-09-27 | Chugai Pharmaceutical Co Ltd | Molécula de unión a antígenos para eliminar antígenos agregados |
| WO2014028354A1 (en) | 2012-08-13 | 2014-02-20 | Regeneron Pharmaceuticals, Inc. | Anti-pcsk9 antibodies with ph-dependent binding characteristics |
| JP6774164B2 (ja) | 2012-08-24 | 2020-10-21 | 中外製薬株式会社 | マウスＦｃγＲＩＩ特異的Ｆｃ抗体 |
| EP3721900A1 (en) | 2012-08-24 | 2020-10-14 | Chugai Seiyaku Kabushiki Kaisha | Fcgammariib-specific fc region variant |
| TW201418707A (zh) | 2012-09-21 | 2014-05-16 | Alexion Pharma Inc | 補體組分ｃ５拮抗劑之篩選分析 |
| CA2899589C (en) | 2013-01-31 | 2022-02-22 | Seoul National University R & Db Foundation | C5 antibody and method for preventing and treating complement-related diseases |
| EP2968985A2 (en) | 2013-03-15 | 2016-01-20 | Amgen, Inc. | Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9 |
| US9321686B2 (en) | 2013-03-15 | 2016-04-26 | Forta Corporation | Reinforcement fiber coating compositions, methods of making and treating, and uses for improved adhesion to asphalt and portland cement concrete |
| KR102318483B1 (ko) | 2013-04-02 | 2021-10-27 | 추가이 세이야쿠 가부시키가이샤 | Ｆｃ영역 개변체 |
| NZ711451A (en) | 2014-03-07 | 2016-05-27 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| US10183994B2 (en) | 2014-06-30 | 2019-01-22 | Merck Patent Gmbh | Anti-TNFα antibodies with pH-dependent antigen binding for improved target clearence |
| TWI617580B (zh) * | 2014-12-19 | 2018-03-11 | 中外製藥股份有限公司 | 抗ｃ５抗體及使用方法 |
| KR102605798B1 (ko) * | 2015-02-05 | 2023-11-23 | 추가이 세이야쿠 가부시키가이샤 | 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용 |
-
2012
- 2012-09-27 TW TW107101835A patent/TW201817745A/zh unknown
- 2012-09-27 TW TW107101834A patent/TW201817744A/zh unknown
- 2012-09-27 TW TW101135493A patent/TW201326209A/zh unknown
- 2012-09-28 RU RU2014117500/10A patent/RU2014117500A/ru unknown
- 2012-09-28 WO PCT/JP2012/006218 patent/WO2013046704A2/en not_active Ceased
- 2012-09-28 EP EP12775324.2A patent/EP2760890B1/en active Active
- 2012-09-28 RU RU2018118993A patent/RU2018118993A/ru not_active Application Discontinuation
- 2012-09-28 MX MX2014003891A patent/MX2014003891A/es unknown
- 2012-09-28 JP JP2014514947A patent/JP6204350B2/ja active Active
- 2012-09-28 AU AU2012313670A patent/AU2012313670B2/en not_active Ceased
- 2012-09-28 CA CA2850035A patent/CA2850035A1/en not_active Abandoned
- 2012-09-28 EP EP19150272.3A patent/EP3549956A3/en not_active Withdrawn
- 2012-09-28 KR KR1020147011698A patent/KR20140069332A/ko not_active Withdrawn
- 2012-09-28 SG SG10201808187TA patent/SG10201808187TA/en unknown
- 2012-09-28 CN CN201810780566.9A patent/CN108948197A/zh not_active Withdrawn
- 2012-09-28 SG SG11201401098TA patent/SG11201401098TA/en unknown
- 2012-09-28 BR BR112014007290A patent/BR112014007290A2/pt active Search and Examination
- 2012-09-28 EP EP23210057.8A patent/EP4324850A3/en active Pending
- 2012-09-28 US US14/347,187 patent/US10253100B2/en active Active
- 2012-09-28 CN CN201280058760.7A patent/CN103958547B/zh not_active Expired - Fee Related
-
2017
- 2017-08-18 AU AU2017216587A patent/AU2017216587B2/en not_active Ceased
- 2017-08-31 JP JP2017166638A patent/JP6541730B2/ja active Active
-
2019
- 2019-01-09 HK HK19100308.6A patent/HK1257946A1/zh unknown
- 2019-02-01 US US16/264,735 patent/US20190233525A1/en not_active Abandoned
- 2019-06-11 JP JP2019108321A patent/JP7001637B2/ja active Active
-
2021
- 2021-12-24 JP JP2021211155A patent/JP2022034037A/ja active Pending
-
2023
- 2023-12-08 US US18/533,360 patent/US20240117059A1/en active Pending
-
2024
- 2024-04-26 JP JP2024072301A patent/JP2024097064A/ja active Pending
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12473375B2 (en) | 2006-03-31 | 2025-11-18 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
| US12116414B2 (en) | 2007-09-26 | 2024-10-15 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in CDR |
| US12122840B2 (en) | 2007-09-26 | 2024-10-22 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in CDR |
| US11891434B2 (en) | 2010-11-30 | 2024-02-06 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
| US11454633B2 (en) | 2014-12-19 | 2022-09-27 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies, polypeptides containing variant Fc regions, and methods of use |
| US12169205B2 (en) | 2014-12-19 | 2024-12-17 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use |
| KR20180125036A (ko) * | 2015-09-18 | 2018-11-21 | 추가이 세이야쿠 가부시키가이샤 | Il-8에 결합하는 항체 및 그의 사용 |
| US12252532B2 (en) | 2015-12-25 | 2025-03-18 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
| KR20200038562A (ko) * | 2016-08-05 | 2020-04-13 | 추가이 세이야쿠 가부시키가이샤 | Il-8 관련 질환의 치료용 또는 예방용 조성물 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230220083A1 (en) | Antibodies with modified affinity to fcrn that promote antigen clearance | |
| JP7001637B2 (ja) | 抗原クリアランスを促進するＦｃＲｎ結合ドメインを有する治療用抗原結合分子 | |
| RU2810471C1 (ru) | АНТИТЕЛА С МОДИФИЦИРОВАННОЙ АФФИННОСТЬЮ К FcRn, КОТОРЫЕ УВЕЛИЧИВАЮТ КЛИРЕНС АНТИГЕНОВ | |
| HK1196623B (zh) | 具有促进抗原清除的fcrn结合结构域的治疗性抗原结合分子 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20140429 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20170927 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20190116 Patent event code: PE09021S01D |
|
| PC1202 | Submission of document of withdrawal before decision of registration |
Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment) Patent event code: PC12021R01D Patent event date: 20190801 |